Cargando…

Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma

The diagnostic and prognostic evaluation of primary central nervous system lymphoma (PCNSL) is challenging due to the lack of sensitive biomarkers. The present study aimed to evaluate the value of interleukin (IL)-10 in this context. Between October 2016 and December 2018, 91 patients with suspected...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Mingying, Song, Yang, Xiao, He, Wu, Zhiyu, Deng, Xiaojuan, Chen, Chuan, Wang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681207/
https://www.ncbi.nlm.nih.gov/pubmed/33240408
http://dx.doi.org/10.3892/ol.2020.12263
_version_ 1783612591907536896
author Geng, Mingying
Song, Yang
Xiao, He
Wu, Zhiyu
Deng, Xiaojuan
Chen, Chuan
Wang, Ge
author_facet Geng, Mingying
Song, Yang
Xiao, He
Wu, Zhiyu
Deng, Xiaojuan
Chen, Chuan
Wang, Ge
author_sort Geng, Mingying
collection PubMed
description The diagnostic and prognostic evaluation of primary central nervous system lymphoma (PCNSL) is challenging due to the lack of sensitive biomarkers. The present study aimed to evaluate the value of interleukin (IL)-10 in this context. Between October 2016 and December 2018, 91 patients with suspected intracranial neoplasms were recruited, and the concentrations of IL-10 or IL-6 in both the cerebrospinal fluid (CSF) and blood were measured and analyzed by the Kruskal-Wallis test. The correlation between CSF IL-6 or IL-10 levels and tumor size was determined by Spearman's coefficient analysis. The receiver operating characteristic curve was used to evaluate the diagnostic value of CSF IL-6 and IL-10 levels. Median progression-free survival (PFS) and overall survival time were calculated using Kaplan-Meier survival analysis. Among the 91 patients, 3 were diagnosed with PCNSL on the basis of neuroimaging data and CSF IL-10 levels. A total of 35 cases were verified to show diffuse large B-cell lymphoma on histological assessment, 17 of which were diagnosed as PCNSL by MRI. The median PFS and OS were 8.00 months [95% confidence interval (CI), 3.94–12.06) and 17.5 months (95% CI, 11.55–23.45) respectively in the 12 PNCSL cases with regular follow up. The diagnostic efficiency of serum IL-6 levels was lower than that of serum IL-10 levels (P=0.030), which, in turn, was lower than that of CSF IL-10 levels (P<0.001). The decline and increase in CSF IL-10 levels was concurrent with improvement and deterioration in manifestation, respectively, which predated the MRI variation. High CSF IL-10 levels indicated low Karnofsky performance scale scores and shortened PFS times. CSF IL-10 levels higher than 1,000 pg/ml signified disease progression. CSF IL-10 levels could be a sensitive biomarker guiding the differential diagnosis, early recurrence detection, prognostic evaluation and therapeutic strategy establishment in cases of PCNSL.
format Online
Article
Text
id pubmed-7681207
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-76812072020-11-24 Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma Geng, Mingying Song, Yang Xiao, He Wu, Zhiyu Deng, Xiaojuan Chen, Chuan Wang, Ge Oncol Lett Articles The diagnostic and prognostic evaluation of primary central nervous system lymphoma (PCNSL) is challenging due to the lack of sensitive biomarkers. The present study aimed to evaluate the value of interleukin (IL)-10 in this context. Between October 2016 and December 2018, 91 patients with suspected intracranial neoplasms were recruited, and the concentrations of IL-10 or IL-6 in both the cerebrospinal fluid (CSF) and blood were measured and analyzed by the Kruskal-Wallis test. The correlation between CSF IL-6 or IL-10 levels and tumor size was determined by Spearman's coefficient analysis. The receiver operating characteristic curve was used to evaluate the diagnostic value of CSF IL-6 and IL-10 levels. Median progression-free survival (PFS) and overall survival time were calculated using Kaplan-Meier survival analysis. Among the 91 patients, 3 were diagnosed with PCNSL on the basis of neuroimaging data and CSF IL-10 levels. A total of 35 cases were verified to show diffuse large B-cell lymphoma on histological assessment, 17 of which were diagnosed as PCNSL by MRI. The median PFS and OS were 8.00 months [95% confidence interval (CI), 3.94–12.06) and 17.5 months (95% CI, 11.55–23.45) respectively in the 12 PNCSL cases with regular follow up. The diagnostic efficiency of serum IL-6 levels was lower than that of serum IL-10 levels (P=0.030), which, in turn, was lower than that of CSF IL-10 levels (P<0.001). The decline and increase in CSF IL-10 levels was concurrent with improvement and deterioration in manifestation, respectively, which predated the MRI variation. High CSF IL-10 levels indicated low Karnofsky performance scale scores and shortened PFS times. CSF IL-10 levels higher than 1,000 pg/ml signified disease progression. CSF IL-10 levels could be a sensitive biomarker guiding the differential diagnosis, early recurrence detection, prognostic evaluation and therapeutic strategy establishment in cases of PCNSL. D.A. Spandidos 2021-01 2020-11-03 /pmc/articles/PMC7681207/ /pubmed/33240408 http://dx.doi.org/10.3892/ol.2020.12263 Text en Copyright: © Geng et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Geng, Mingying
Song, Yang
Xiao, He
Wu, Zhiyu
Deng, Xiaojuan
Chen, Chuan
Wang, Ge
Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma
title Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma
title_full Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma
title_fullStr Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma
title_full_unstemmed Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma
title_short Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma
title_sort clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681207/
https://www.ncbi.nlm.nih.gov/pubmed/33240408
http://dx.doi.org/10.3892/ol.2020.12263
work_keys_str_mv AT gengmingying clinicalsignificanceofinterleukin10concentrationinthecerebrospinalfluidofpatientswithprimarycentralnervoussystemlymphoma
AT songyang clinicalsignificanceofinterleukin10concentrationinthecerebrospinalfluidofpatientswithprimarycentralnervoussystemlymphoma
AT xiaohe clinicalsignificanceofinterleukin10concentrationinthecerebrospinalfluidofpatientswithprimarycentralnervoussystemlymphoma
AT wuzhiyu clinicalsignificanceofinterleukin10concentrationinthecerebrospinalfluidofpatientswithprimarycentralnervoussystemlymphoma
AT dengxiaojuan clinicalsignificanceofinterleukin10concentrationinthecerebrospinalfluidofpatientswithprimarycentralnervoussystemlymphoma
AT chenchuan clinicalsignificanceofinterleukin10concentrationinthecerebrospinalfluidofpatientswithprimarycentralnervoussystemlymphoma
AT wangge clinicalsignificanceofinterleukin10concentrationinthecerebrospinalfluidofpatientswithprimarycentralnervoussystemlymphoma